Cue Biopharma (NASDAQ: CUE) reported a widening loss in its second-quarter results, with net loss expanding to $153.1 million. This figure missed the analyst consensus estimate of $(1.69) per share significantly, driven by substantial one-time non-cash charges and acquisition-related payments. The per-share loss widened to $(24.14), a sharp deterioration from the $(2.70) per share loss recorded in the same period last year.

Despite the pressure on profitability, the company delivered strong top-line performance. Quarterly sales rose to $7.877 million, surpassing the analyst consensus estimate of $3.000 million by 162.57 percent. This represents a 166.66 percent increase over the $2.954 million in sales reported during the same quarter of the previous fiscal year, driven by revenue earned from the Boehringer Ingelheim collaboration upon achievement of a preclinical milestone.

Operational and Financial Drivers

The widening loss was primarily attributable to non-recurring items related to the company’s strategic transformation and the licensing of CUE-221 from Ascendant Therapeutics.

Research and development expenses surged to $49.0 million from $7.9 million in the prior year period. This increase included approximately $20.0 million in one-time cash payments for the upfront payment to Ascendant and transaction costs, as well as $20.0 million recognized as the fair value of warrants issued to Ascendant. The latter resulted in a corresponding credit to shareholders’ equity, creating no net impact on stockholders’ equity.

General and administrative expenses also spiked to $46.6 million from $3.7 million in 2025. This rise was driven by approximately $23.0 million in one-time expenses related to integration with a newly assembled management team and transaction costs, alongside $19.7 million in non-cash stock-based compensation.

Other income and expense recorded a net non-cash loss of $63.1 million, primarily due to the loss on issuance of liability-classified warrants under the license agreement, partially offset by a gain on fair value measurement of warrants issued.

What the Numbers Show

The divergence between revenue growth and profit performance highlights that the reported loss is largely non-operational and non-cash in nature. While sales more than doubled year-over-year (up 166.66%), the per-share loss expanded dramatically from $(2.70) to $(24.14). A significant portion of this expansion stems from the $63.1 million non-cash warrant loss and $40 million in one-time R&D/license-related charges. Excluding these specific non-recurring and non-cash items, the underlying operational burn rate, while elevated due to strategic transformation costs ($23M G&A), remains distinct from the headline net loss figure. Investors should note that the $50 million private placement completed subsequent to June 30, 2026, provides fresh liquidity to fund clinical development.

Business Highlights

The company announced several key business developments alongside the financial results:

• CUE-221 Progress: Submitted an Investigational New Drug (IND) application to the FDA for food allergy applications. Phase 2 data readout in Chronic Spontaneous Urticaria is anticipated by the end of the third quarter of 2026.
• CUE-401 Pipeline: Anticipates submitting an IND to the FDA and initiating a Phase 1 clinical study by year-end 2026.
• Leadership Appointments: Strengthened the leadership team with the appointment of Dr. Dominic Borie as Chief Medical Officer and Head of R&D, and Mr. James M. Ahlers as Chief Financial Officer.
• Financing: Completed a $50 million private placement (PIPE) to fund clinical development and portfolio advancement.

As of June 30, 2026, Cue Biopharma had $17.4 million in cash and cash equivalents. The company’s ability to convert this revenue growth into long-term profitability will be a key focus for investors as it navigates its current financial trajectory and advances its pipeline.

Cue Biopharma Inc. filed a prospectus with the US Securities and Exchange Commission (SEC) to facilitate the resale of shares issued in its recent capital raise. The filing covers 1,505,570 shares, which includes 87,500 underlying pre-funded warrants.

The securities were originally issued as part of a $50 million private placement completed in July. The prospectus allows selling security holders to offer these shares in the public market.

Transaction Details

The filing discloses the specific composition of the shares eligible for resale under the prospectus:

The company did not disclose additional financial metrics or operational updates in this specific filing. The primary purpose of the document is to register the resale rights associated with the July transaction.